Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
NCT06005324
Recruiting
This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: HPV-Negative Squamous Cell Carcinoma
Register for Updates
FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer
NCT06338657
Recruiting
This phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) affects the immune cells around the tumor patients with head and neck squamous cell carcinoma. The active drug in FID-007 is paclitaxel, an established chemotherapy drug that has been shown to kill cancer cells. FID-007 is a packaged form of paclitaxel using a polyethylozaxoline (PEOX) polymer which may allow the drug to reach deeper into tumors and less into normal cells by being smaller. This stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Los Angeles General Medical Center, Los Angeles, California +1 locations
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
NCT05827055
Recruiting
This is a Phase 2 study with an open labelled lead-in study to approximately treat 30 patients \[6 subjects for Lead-in and 24 for Phase 2\] enrolled with metastatic pancreatic cancer with combination therapy using standard of care first line therapy with GEM-NAB-P (GEM 1000mg/m2 IV and NAB-P 125 mg/m2 given days 1, 8, and 15 every 28 days, and proglumide will be tested at the daily dose of 1200 mg orally given as 400 mg po TID. The lead-in study will determine the safety and tolerability of the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia
Conditions: Metastatic Pancreatic Cancer
Register for Updates
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
NCT04858269
Recruiting
The purpose of this research is to see what effects the treatment regimen chemotherapy (carboplatin and paclitaxel) plus immunotherapy (pembrolizumab), has on patients who have been diagnosed with head/neck squamous cell carcinoma and are unable to take the drug 5-fluorouracil
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Wake Forest Baptist Health Sciences, Winston-Salem, North Carolina
Conditions: Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
Register for Updates
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
NCT04055649
Recruiting
This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent), or that does not respond to treatment (refractory). ONC201 is the first in its class of drugs that antagonize some specific cell receptors on cancer cells, leading to their destruction. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan +1 locations
Conditions: Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
Register for Updates
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
NCT04390763
Terminated
The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in untreated mPDAC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Winship Cancer Institute Main Centre, Atlanta, Georgia +30 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT02186847
Active Not Recruiting
This randomized phase II trial studies how well chemotherapy and radiation therapy given with or without metformin hydrochloride works in treating patients with stage III non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. M... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Lewis and Faye Manderson Cancer Center, Tuscaloosa, Alabama +223 locations
Conditions: Adenosquamous Lung Carcinoma, Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Non-Small Cell Lung Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Squamous Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
Register for Updates
RegoNivo vs Standard of Care Chemotherapy in AGOC
NCT04879368
Active Not Recruiting
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +93 locations
Conditions: Gastro-Oesophageal Cancer
Register for Updates
QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NCT03136406
Terminated
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care first line therapy and chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Chan Soon-Shiong Institute for Medicine, El Segundo, California
Conditions: Pancreatic Cancer
Register for Updates
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
NCT04672005
Active Not Recruiting
The main objective of the clinical trial is to determine if modified FOLFIRINOX (mFFX) alternated with biweekly Gemcitabine plus Nab-Paclitaxel (mGnabP) administered as a combined, front-line therapy will result in longer time to treatment failure (TTF) compared to the current standard of care with mFFX alone in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: RWJBarnabas Health - Robert Wood Johnson University Hospital, Hamilton, Hamilton, New Jersey +6 locations
Conditions: Metastatic Pancreatic Cancer
Register for Updates
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
NCT04527900
Recruiting
A phase 2 study with the primary objective of testing treatment compliance of Upfront Intensity Modulated Proton Beam Therapy (IMPT) and Concurrent Chemotherapy (UPPROACH) for Post-operative Treatment in Loco-regionally Advanced Endometrial Cancer is non-inferior to the historic compliance rate of the chemoradiation arm of GOG 258 study
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: Maryland Proton Treatment Center, Baltimore, Maryland +3 locations
Conditions: Endometrial Cancer
Register for Updates
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
NCT05921149
Not Yet Recruiting
Rates of grade 3-4 toxicity with carboplatin and paclitaxel chemotherapy range 26-84%. Interventions to reduce toxicity are needed. Short term fasting protects against toxic effects of chemotherapy without decreasing efficacy. In a prospective clinical trial of breast cancer patients randomized to FMD or regular diet during chemotherapy, less antiemetic was required in the FMD group; radiographic and pathologic responses were better in this group. This trial tests whether platinum-taxane chemo... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/05/2024
Locations: NorthShore University HealthSystem, Evanston, Illinois
Conditions: Ovarian Cancer, Chemotherapeutic Toxicity
Register for Updates